Successful treatment with adapted high dose methotrexate in a hemodialysis patient with primary central nervous system lymphoma: 100 mg/m2 seems sufficient - Archive ouverte HAL Access content directly
Journal Articles Nefrologia Year : 2022

Successful treatment with adapted high dose methotrexate in a hemodialysis patient with primary central nervous system lymphoma: 100 mg/m2 seems sufficient

(1) , (2) , (3, 4) , (5) , (6) , (7) , (5, 8, 9) , (7)
1
2
3
4
5
6
7
8
9

Abstract

High dose methotrexate (HD-MTX) based chemoimmunotherapy is a central part of the standard approach to treatment of primary central nervous system lymphoma (PCNSL). Renal dysfunction leads to delayed MTX complete elimination and critical MTX concentration. Despite the recommendations, hemodialysis status should not exclude HD-MTX. We report the case of a 64 years old woman on chronic hemodialysis with PCNSL successfully treated with HD-MTX-based chemoimmunotherapy with an adjusted dose of 100 mg/m(2), instead of the usual dose of 3500 mg/m(2), and daily hemodialysis started 24 h later. The patient had no significant toxicity and was in complete remission at 1 year after the end of the treatment. We argue that ESRD is not an absolute pitfall to the use of HD-MTX for hematological malignancies. Experts should consider the use of adjusted dose at 100 mg/m(2) as a viable therapeutic modality in ESRD patients. (C) 2021 Sociedad Espanola de Nefrologia. Published by Elsevier Espana, S.L.U.

Dates and versions

hal-03726638 , version 1 (18-07-2022)

Identifiers

Cite

Justine Solignac, Laure Farnault, Thomas Robert, Raphaelle Fanciullino, Sylvain Choquet, et al.. Successful treatment with adapted high dose methotrexate in a hemodialysis patient with primary central nervous system lymphoma: 100 mg/m2 seems sufficient. Nefrologia, 2022, 42 (2), pp.130-134. ⟨10.1016/j.nefro.2021.03.004⟩. ⟨hal-03726638⟩
13 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More